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PHARMACY UPDATE  Joshua Bird, Pharm.D Student & Deepti Vyas, Pharm D 
The Future of Warfarin Dosing: What is in the Pipeline? 
Pharmacogenetic testing has been researched to find genetic variability among individuals who require war-
farin therapy and to possibly reduce the occurrence of adverse events; indeed, the FDA recently approved a 
labeling change for Coumadin and issued a statement that “lower initiation doses should be considered for 
patients with certain genetic variations in the CYP2C9 and VKORC1 enzymes.”  The latter enzymes are the 
primary agents in the metabolism of warfarin; researches have found 37 different alleles for the CYP2C9 gene 
with CYP2C9*1 representing the wild (normal metabolizer) type. 
Patients who are homozygous for a variant allele generally require less warfarin.  The most common variants 
are CYP2C9*2 and CYP2C9*3, with the latter producing the slowest metabolism of warfarin.  The variant al-
leles have been found to be most common in European-American and African-American populations.  While 
studies demonstrate that pharmacogenetic testing helps to guide dosing and improve safety, it remains to be 
seen whether such testing proves to be cost effective. 
Reference:  Limdi, NA & DL Veenstra, Warfarin Pharmacogenomics, Pharmacotherapy, 2008, 28(9), 1084-97 
 
CASE REPORT       Robert Folzenlogen MD 
A 76 year old male was transferred to MU for management of pneumonia and rhabdomyolysis.  He gave a 
history of cough, green sputum, fever, chills and malaise for the past several weeks; these symptoms did not 
improve after a 14 day course of Augmentin.  He developed increasing weakness, anorexia and an inability to 
stand up and was taken to his local ER for evaluation.  His chronic mild dyspnea had begun to increase and he 
gave a vague history of weight loss; he denied hemoptysis.  Evaluation in the ER revealed WBC 32.3 with 88 
segs, Hgb 10.4, BUN 35, Cr 2.6 and CK 1706.  A CT of the head was negative but a CXR showed a RUL  infil-
trate.  He was transferred to MU for further evaluation and management. 
The patient reported a history of pulmonary fibrosis (diagnosed in 1989), chronic kidney disease secondary to 
ANCA+ vasculitis (since 2003), peripheral neuropathy and myelodysplastic syndrome.  Medications included 
Prednisone 5mg qd and Cytoxan every 14 weeks.  He lives and works on a farm where he raises pigs and 
grows corn, beans and wheat.  Pets include a dog and three cats.  He quit tobacco use 20 years ago and 
stopped using alcohol several years ago; he denied any past use of illicit drugs.  He was in the Navy during the 
Korean war.  Though he was a hunter, he has not done so for 6 years and has not travelled over the past six 
months; he denied recent tick bites.  He also denied a past +PPD, history of TB or exposure to TB. 
Initial exam revealed a weak, lethargic, elderly male who was otherwise in no acute distress.  T was 38.2 and 
BP was 132/92.  No rash or jaundice was noted.  HEENT was unremarkable except for poor dentition.  Neck 
revealed no adenopathy or JVD.  Chest was reported to be clear and cardiovascular exam was normal; there 
was no peripheral edema.  Abdominal exam was normal with no organomegaly or tenderness. 
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